SJS Investment Consulting
NPCE icon

SJS Investment Consulting’s Neuropace NPCE Stock Holding History

SJS Investment Consulting’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.16K Buy
84
+75
+833% +$1.11K ﹤0.01% 2442
2026
Q2 		$144 Buy
9
+1
+13% +$16 ﹤0.01% 2534
2026
Q1 		$106 Buy
+8
New +$120 ﹤0.01% 2126

Other funds holding NPCE

Essex Investment Management
Essex Investment Management Boston, Massachusetts $675M AUM 61.81% 1-Year Est. Return
Nisa Investment Advisors
Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return
Sterling Capital Management
Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return
Root Financial Partners
Root Financial Partners Encinitas, California $2.98B AUM 13.9% 1-Year Est. Return
SBI Securities
SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return
Caitong International Asset Management
Caitong International Asset Management Hong Kong $1.04B AUM 150.25% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
Hughes Financial Services
Hughes Financial Services Herndon, Virginia $786M AUM 13.15% 1-Year Est. Return

SJS Investment Consulting's NPCE Position: Q3 2026 in Review

SJS Investment Consulting increased its Neuropace (NPCE) stake by 833% in Q3 2026, buying an estimated $1.11K and bringing the position to 84 shares worth $1.16K. The position accounts for ﹤0.01% of the portfolio, ranked #2442.

SJS Investment Consulting first reported a position in NPCE in Q1 2026 and has held it in 3 quarters since. 10 funds tracked by Wall St. Rank hold NPCE as of Q3 2026.

  • SJS Investment Consulting held 84 shares of Neuropace worth $1.16K as of Q3 2026.
  • SJS Investment Consulting bought 75 Neuropace shares in Q3 2026, an estimated $1.11K.
  • Neuropace made up ﹤0.01% of SJS Investment Consulting's portfolio in Q3 2026, its #2442 holding.
  • SJS Investment Consulting first reported a position in Neuropace in Q1 2026 and has held it in 3 quarters since.
  • 10 funds tracked by Wall St. Rank held Neuropace as of Q3 2026.

Based on SJS Investment Consulting's 13F filing for Q3 2026, filed 26 Oct 2026.